Erythroferrone undergoing commercial development
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Under a license from UCLA, Intrinsic LifeSciences has developed a "research use only" assay for human erythroferrone sold to many clinical researchers worldwide. Quoting from the Silarus website, erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches. Iron overload is a condition in which too much iron builds up in the body, causing organ poisoning or failure. Silarus was founded based on intellectual property in-licensed from investigators Tomas Ganz, M.D., Ph.D., Professor of Medicine, Department of Pathology and Laboratory Medicine and Elizabeta Nemeth, Ph.D., Associate Professor of Medicine, Division of Pulmonary and Critical Care, both of the University of California, Los Angeles, David Geffen School of Medicine.
Read more here